BEBT-109 + pemetrexed + carboplatin

BEBT-109 + pemetrexed + carboplatin is a three-drug combination therapy under clinical investigation for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. **BEBT-109** is an oral pan-mutant-selective inhibitor of epidermal growth factor receptor (EGFR) that targets multiple EGFR mutants while sparing wild-type EGFR. It has shown potent antitumor activity and favorable safety in preclinical and early clinical studies[1][5][3][7]. **Pemetrexed** is a multi-targeted antifolate chemotherapeutic agent that inhibits several folate-dependent enzymes involved in nucleotide synthesis, while **carboplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA replication and transcription. The combination is designed to provide targeted therapy against mutated EGFR along with cytotoxic chemotherapy. This regimen is being studied as a potential first-line treatment for patients with locally advanced, recurrent, or metastatic NSCLC with EGFR exon 20 insertion mutations[7].

Other names

pemetrexedcarboplatin